<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals Ltd filed a routine Initial Large Corporate Disclosure with BSE and NSE on April 23, 2025, as required under SEBI Circular dated October 19, 2023. The company confirmed that it does not fall under the category of 'Large Corporates' as on March 31, 2025, since the specified criteria are not applicable to it. All key disclosures in Annexure-A, including outstanding borrowings, highest credit rating, and stock exchange for fine payment, are marked as 'Not Applicable'. The filing was signed by the Company Secretary (Trusha Shah) and Chief Financial Officer (Darshit Shah).
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms the company is below the threshold that would classify it as a Large Corporate under SEBI's borrowing framework.